Peripheral artery disease: Evolving role of exercise, medical therapy, and endovascular options

Journal of the American College of Cardiology

Volumn 67, Issue 11, 2016, Pages 1338-1357

  Olin, Jeffrey W ^a   White, Christopher J ^b   Armstrong, Ehrin J ^c,d   Kadian Dodov, Daniella ^a   Hiatt, William R ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d Veterans Affairs Eastern Colorado Healthcare System   (United States)

Author keywords

ankle brachial index; claudication; drug eluting stents; endovascular therapy; exercise therapy; vascular diseases

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAFTIDROFURYL; PENTOXIFYLLINE; PLACEBO; RAMIPRIL; RIVAROXABAN; SIMVASTATIN; TELMISARTAN; VORAPAXAR; CARDIOVASCULAR AGENT;

ANTIANGIOGENIC THERAPY; ARTERY DISEASE; ATHERECTOMY; BARE METAL STENT; BYPASS SURGERY; CARDIOVASCULAR RESPONSE; CLAUDICATION; CLINICAL TRIAL (TOPIC); COMMON FEMORAL ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DEEP FEMORAL ARTERY; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG SAFETY; ENDARTERECTOMY; EXERCISE; FEMORAL POPLITEAL DISEASE; HEALTH CARE COST; HOME CARE; HUMAN; LERICHE SYNDROME; MORBIDITY; PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; RISK REDUCTION; SMOKING CESSATION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; WALKING; ENDOVASCULAR SURGERY; KINESIOTHERAPY; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; ENDOVASCULAR PROCEDURES; EXERCISE THERAPY; HUMANS; PERIPHERAL ARTERIAL DISEASE; TREATMENT OUTCOME;

EID: 84962850881     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.12.049     Document Type: Review

References (128)

1. M.R. Patel, M.S. Conte, D.E. Cutlip, and et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC) [published correction appears in J Am Coll Cardiol 2015;65:2578-2579] J Am Coll Cardiol 65 2015 931 941
2. T.W. Rooke, A.T. Hirsch, S. Misra, and et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 61 2013 1555 1570
3. M. Tendera, V. Aboyans, M. Bartelink, and et al. ESC guidelines on the diagnosis and treatment of peripheral artery disease Eur Heart J 32 2011 2851 2906
4. L. Norgren, W.R. Hiatt, J.A. Dormandy, et al. TASC II Working Group Inter-society Consensus for the Management of Peripheral Arterial Disease (TASC II) Eur J Vasc Endovasc Surg 33 Suppl 1 2007 S1 S75
5. TASC Steering Committee M.R. Jaff, C.J. White, and et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) Vasc Med 20 2015 465 478
6. F.G. Fowkes, D. Rudan, I. Rudan, and et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis Lancet 382 2013 1329 1340
7. U. Sampson, F. Fowkes, M. McDermott, and et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990-2010 Glob Heart 9 2014 145 158.e21
8. R.L. Pande, T.S. Perlstein, J.A. Beckman, and et al. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004 Circulation 124 2011 17 23
9. A.T. Hirsch, M.H. Criqui, D. Treat-Jacobson, and et al. Peripheral arterial disease detection, awareness, and treatment in primary care JAMA 286 2001 1317 1324
10. E. Selvin, and T.P. Erlinger Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000 Circulation 110 2004 738 743
11. M.R. Nehler, S. Duval, L. Diao, and et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population J Vasc Surg 60 2014 686 695.e2
12. E.J. Armstrong, D.C. Chen, G.G. Westin, and et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral artery disease J Am Heart Assoc 3 2014 e000697
13. M.H. Criqui, and V. Aboyans Epidemiology of peripheral artery disease Circ Res 116 2015 1509 1526
14. M.M. Joosten, J.K. Pai, M.L. Bertoia, and et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men JAMA 308 2012 1660 1667
15. G.C. Leng, F.G. Fowkes, A.J. Lee, J. Dunbar, E. Housley, and C.V. Ruckley Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study BMJ 313 1996 1440 1444
16. M.H. Criqui, R.D. Langer, A. Fronek, and et al. Mortality over a period of 10 years in patients with peripheral arterial disease N Engl J Med 326 1992 381 386
17. M.M. McDermott, P. Greenland, K. Liu, and et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment JAMA 286 2001 1599 1606
18. M.M. McDermott, K. Liu, P. Greenland, and et al. Functional decline in peripheral artery disease: associations with the ankle brachial index and leg symptoms JAMA 292 2004 453 461
19. M.M. McDermott, J.M. Guralnik, L. Tian, and et al. Associations of borderline and low normal ankle-brachial index values with functional decline at 5-year follow-up: the WALCS (Walking and Leg Circulation Study) J Am Coll Cardiol 53 2009 1056 1062
20. M.M. McDermott, P. Greenland, L. Tian, and et al. Association of 6-minute walk performance and physical activity with incident ischemic heart disease events and stroke in peripheral artery disease J Am Heart Assoc 4 2015 e001846
21. V. Aboyans, M.H. Criqui, P. Abraham, et al. for the American Heart Association Council on Peripheral Vascular Disease Council on Epidemiology and Prevention Council on Clinical Cardiology Council on Cardiovascular Nursing Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association [published correction appears in Circulation 2013;127:e264] Circulation 126 2012 2890 2909
22. H.E. Resnick, R.S. Lindsay, M.M. McDermott, and et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study Circulation 109 2004 733 739
23. Ankle Brachial Index Collaboration Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis JAMA 300 2008 197 208
24. J.Y. Lee, S.W. Lee, W.S. Lee, and et al. Prevalence and clinical implications of newly revealed, asymptomatic abnormal ankle-brachial index in patients with significant coronary artery disease J Am Coll Cardiol Intv 6 2013 1303 1313
25. C. Diehm, A. Schuster, J.R. Allenberg, and et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study Atherosclerosis 172 2004 95 105
26. J.P. Cooke, and A.M. Wilson Biomarkers of peripheral arterial disease J Am Coll Cardiol 55 2010 2017 2023
27. W.R. Hiatt, A. Zakharyan, E.T. Fung, and et al. A validated biomarker panel to identify peripheral artery disease Vasc Med 17 2012 386 393
28. M.M. McDermott, K. Liu, D. Green, and et al. Changes in D-dimer and inflammatory biomarkers before ischemic events in patients with peripheral artery disease: The BRAVO Study Vasc Med 21 2016 12 20
29. W.R. Hiatt, E.J. Armstrong, C.J. Larson, and E.P. Brass Pathogenesis of the limb manifestations and exercise limitations in peripheral artery disease Circ Res 116 2015 1527 1539
30. M.M. McDermott, S. Mehta, and P. Greenland Exertional leg symptoms other than intermittent claudication are common in peripheral artery disease Arch Intern Med 159 1999 387 392
31. T. Gorely, H. Crank, L. Humphreys, S. Nawaz, and G.A. Tew "Standing still in the street": experiences, knowledge and beliefs of patients with intermittent claudication: a qualitative study J Vasc Nurs 33 2015 4 9
32. M.A. Cunningham, V. Swanson, E. Pappas, R.E. O'Carroll, and R.J. Holdsworth Illness beliefs and walking behavior after revascularization for intermittent claudication: a qualitative study J Cardiopulm Rehabil Prev 34 2014 195 201
33. W.R. Hiatt, J.G. Regensteiner, M.E. Hargarten, E.E. Wolfel, and E.P. Brass Benefit of exercise conditioning for patients with peripheral arterial disease Circulation 81 1990 602 609
34. W.R. Hiatt, E.E. Wolfel, R.H. Meier, and J.G. Regensteiner Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease: implications for the mechanism of the training response Circulation 90 1994 1866 1874
35. W.R. Hiatt, J.G. Regensteiner, E.E. Wolfel, M.R. Carry, and E.P. Brass Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease J Appl Physiol (1985) 81 1996 780 788
36. R. Mays, R. Rogers, W.R. Hiatt, and J.G. Regensteiner Community walking programs for treatment of peripheral artery disease J Vasc Surg 58 2013 1678 1687
37. P. Chang, K.T. Nead, J.W. Olin, J. Myers, J.P. Cooke, and N.J. Leeper Effect of physical activity assessment on prognostication for peripheral artery disease and mortality Mayo Clin Proc 90 2015 339 345
38. S. Sakamoto, N. Yokoyama, Y. Tamori, K. Akutsu, H. Hashimoto, and S. Takeshita Patients with peripheral artery disease who complete 12-week supervised exercise training program show reduce cardiovascular mortality and morbidity Circ J 73 2009 167 173
39. A.W. Gardner, P.S. Montgomery, and D.E. Parker Optimal exercise program length for patients with claudication J Vasc Surg 55 2012 1346 1354
40. M.A. Popplewell, and A.W. Bradbury Why do health systems not fund supervised exercise programmes for intermittent claudication? Eur J Vasc Endovasc Surg 48 2014 608 610
41. T.C. Collins, S. Lunos, T. Carlson, and et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized control trial Diabetes Care 34 2011 2174 2179
42. R.J. Mays, W.R. Hiatt, I.P. Casserly, and et al. Community-based walking exercise for peripheral artery disease: an exploratory pilot study Vasc Med 20 2015 339 347
43. A.W. Gardner, D.E. Parker, P.S. Montgomery, K.J. Scott, and S.M. Blevins Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial Circulation 123 2011 491 498
44. A.W. Gardner, D.E. Parker, P.S. Montgomery, and S.M. Blevins Step-monitored home exercise improves ambulation, vascular function, and inflammation in symptomatic patients with peripheral artery disease: a randomized controlled trial J Am Heart Assoc 3 2014 e001107
45. M.M. McDermott, K. Domanchuk, K. Liu, and et al. The Group Oriented Arterial Leg Study (GOALS) to improve walking performance in patients with peripheral arterial disease Contemp Clin Trials 33 2012 1311 1320
46. M.M. McDermott, K. Liu, J.M. Guralnik, and et al. Home-based walking exercise intervention in peripheral artery disease: a randomized control trial JAMA 310 2013 57 65
47. M.M. McDermott, J.M. Guralnik, M.H. Criqui, and et al. Home-based exercise in peripheral artery disease: 12-month follow-up of the GOALS randomized trial J Am Heart Assoc 3 2014 e000711
48. M.M. McDermott, J.M. Guralnik, M.H. Criqui, and et al. Unsupervised exercise and mobility loss in peripheral artery disease: a randomized controlled trial J Am Heart Assoc 4 2015 e001659
49. M.D. Weinberg, J.F. Lau, K. Rosenfield, and J.W. Olin Peripheral artery disease, part 2: medical and endovascular treatment Nat Rev Cardiol 8 2011 429 441
50. U.G. Bronas, A.T. Hirsch, T. Murphy, et al. for the CLEVER Research Group Design of the multicenter standardized supervised exercise training intervention for the CLaudication: Exercise Vs Endoluminal Revascularization (CLEVER) study Vasc Med 14 2009 313 321
51. N.M. Hamburg, and G.J. Balady Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits Circulation 123 2011 87 97
52. T.P. Murphy, D.E. Cutlip, J.G. Regensteiner, et al. for the CLEVER Study Investigators Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) study Circulation 125 2012 130 139
53. J. Nordanstig, C. Taft, M. Hensäter, A. Perlander, K. Osterberg, and L. Jivegård Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial Circulation 130 2014 939 947
54. F. Lundgren, A. Dahllöf, K. Lundholm, T. Scherstén, and R. Volkmann Intermittent claudication: surgical reconstruction or physical training? A prospective randomized trial of treatment efficiency Ann Surg 209 1989 346 355
55. T.P. Murphy, D.E. Cutlip, J.G. Regensteiner, and et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study [published correction appears in J Am Coll Cardiol 2015;65:2055] J Am Coll Cardiol 65 2015 999 1009
56. F. Fakhry, S. Spronk, L. van der Laan, and et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial JAMA 314 2015 1936 1944
57. S. Spronk, J.L. Bosch, P.T. den Hoed, H.F. Veen, P.M. Pattynama, and M.G. Hunink Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial J Vasc Surg 48 2008 1472 1480
58. H.J. Fokkenrood, M.R. Scheltinga, M.J. Koelemay, and et al. Significant savings with a stepped care model for treatment of patients with intermittent claudication Eur J Vasc Endovasc Surg 48 2014 423 429
59. S. Subherwal, M.R. Patel, L. Kober, and et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains Circulation 126 2012 1345 1354
60. J.W. Olin, D.E. Allie, M. Belkin, and et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease) J Am Coll Cardiol 56 2010 2147 2181
61. E.J. Armstrong, J. Wu, G.D. Singh, and et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease J Vasc Surg 60 2014 1565 1571
62. Dartmouth-Hitchcock Medical Center. Vascular Physician Offer and Report (VAPOR) Trial. 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT02220686?term=NCT+02220686&rank=1. Accessed January 7, 2016.
63. D.L. Dawson, B.S. Cutler, M.H. Meissner, and D.E. Strandness Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial Circulation 98 1998 678 686
64. R.L. Pande, W.R. Hiatt, P. Zhang, N. Hittel, and M.A. Creager A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication Vasc Med 15 2010 181 188
65. W.R. Hiatt, S.R. Money, and E.P. Brass Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-Term Effects) J Vasc Surg 47 2008 330 336
66. T. De Backer, R. Vander Stichele, P. Lehert, and L. Van Bortel Naftidrofuryl for intermittent claudication: meta-analysis based on individual patient data BMJ 338 2009 b603
67. Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published corrections appear in N Engl J Med 2000;342:1376 and N Engl J Med 2000;342:748] N Engl J Med 342 2000 145 153
68. J. Östergren, P. Sleight, G. Dagenais, and et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease Eur Heart J 25 2004 17 24
69. ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559
70. E.J. Armstrong, D.C. Chen, G.D. Singh, E.A. Amsterdam, and J.R. Laird Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use in associated with reduced major adverse cardiovascular events among patients with critical limb ischemia Vasc Med 20 2015 237 244
71. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol 2014;63(25 pt B):3024-30325] J Am Coll Cardiol 63 2014 2889 2934
72. Heart Protection Study Collaborative Group Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions J Vasc Surg 45 2007 645 654
73. G.G. Westin, E.J. Armstrong, H. Bang, and et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia J Am Coll Cardiol 63 2014 682 690
74. D.J. Kumbhani, P.G. Steg, C.P. Cannon, et al. on behalf of the REACH Registry Investigators Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry Eur Heart J 35 2014 2864 2872
75. T.R. Vogel, V.Y. Dombrovskiy, E.L. Galiñanes, and R.L. Kruse Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population Circ Cardiovasc Interv 6 2013 694 700
76. J.S. Berger, M.J. Krantz, J.M. Kittelson, and W.R. Hiatt Aspirin for the prevention of cardiovascular events in a general population screened for a low ankle-brachial index: a randomized controlled trial JAMA 301 2009 1909 1919
77. F.G. Fowkes, J.F. Price, M.C. Stewart, et al. for the Aspirin for Asymptomatic Atherosclerosis Trialists Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial JAMA 303 2010 841 848
78. Belch J, MacCuish A, Campbell I, et al.; on behalf of the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.
79. D.A. Morrow, E. Braunwald, M.P. Bonaca, et al. for the TRA 2P-TIMI 50 Steering Committee and Investigators Vorapaxar in the secondary prevention of atherothrombotic events N Engl J Med 366 2012 1404 1413
80. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
81. D.L. Bhatt, K.A.A. Fox, W. Hacke, et al. for the CHARISMA Investigators Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events N Engl J Med 354 2006 1706 1717
82. P.P. Cacoub, D.L. Bhatt, P.G. Steg, E.J. Topol, M.A. Creager for the CHARISMA Investigators Patients with peripheral arterial disease in the CHARISMA Trial Eur Heart J 30 2009 192 201
83. E.J. Armstrong, D.R. Anderson, K.K. Yeo, and et al. Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease J Vasc Surg 62 2015 157 165.e1
84. J.J.F. Belch, J. Dormandy for the CASPAR Writing Committee Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) Trial [published correction appears in J Vasc Surg 2011;53:564] J Vasc Surg 52 2010 825 833 833.e1-2
85. University of Texas Southwestern Medical Center. Antiplatelet Strategy For Peripheral Arterial Interventions for Revascularization of Lower Extremities (ASPIRE PAD). 2014. Available at: https://clinicaltrials.gov/ct2/show/NCT02317822?term=NCT+02317822&rank=1. Accessed January 7, 2016.
86. W.S. Jones, P. Tricoci, Z. Huang, and et al. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) Am Heart J 168 2014 588 596
87. M.P. Bonaca, B.M. Scirica, M.A. Creager, and et al. Vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50 Circulation 127 2013 1522 1529
88. J.P. Cooke, and D.W. Losordo Modulating the vascular response to limb ischemia: angiogenic and cell therapies Circ Res 116 2015 1561 1578
89. N.K. Gupta, E.J. Armstrong, and S.A. Parikh The current state of stem cell therapy for peripheral artery disease Curr Cardiol Rep 16 2014 447
90. AstraZeneca. A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID). 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01732822?term=NCT01732822&rank=1www.clinicaltrials.gov. Accessed January 7, 2016.
91. Bayer. Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Coronary or Peripheral Artery Disease (COMPASS). 2016. Available at: https://clinicaltrials.gov/ct2/show/NCT01776424?term=NCT01776424&rank=1. Accessed January 7, 2016.
92. J.A. Beckman, and M.A. Creager Critical limb ischemia and intermediate-term survival J Am Coll Cardiol Intv 7 2014 1450 1452
93. O. Iida, Y. Soga, D. Kawasaki, and et al. Long-term results of direct and indirect endovascular revascularization based on the angiosome concept in patients with critical limb ischemia presenting with isolated below-the-knee lesions J Vasc Surg 55 2012 363 370.e5
94. V. Jongkind, G.J. Akkersdijk, K.K. Yeung, and W. Wisselink A systematic review of endovascular treatment of extensive aortoiliac occlusive disease J Vasc Surg 52 2010 1376 1383
95. A.J. Klein, D.N. Feldman, H.D. Aronow, and et al. SCAI expert consensus statement for aorto-iliac arterial intervention appropriate use Catheter Cardiovasc Interv 84 2014 520 528
96. G. de Donato, M. Bosiers, F. Setacci, and et al. 24-Month data from the BRAVISSIMO: a large-scale prospective registry on iliac stenting for TASC A & B and TASC C & D lesions Ann Vasc Surg 29 2015 738 750
97. R.F. Bonvini, A. Rastan, S. Sixt, and et al. Endovascular treatment of common femoral artery disease: medium-term outcomes of 360 consecutive procedures J Am Coll Cardiol 58 2011 792 798
98. B.N. Nguyen, R.L. Amdur, M. Abugideiri, R. Rahbar, R.F. Neville, and A.N. Sidawy Postoperative complications after common femoral endarterectomy J Vasc Surg 61 2015 1489 1494.e1
99. M.D. Dake, G.M. Ansel, M.R. Jaff, et al. on behalf of the Zilver PTX Investigators Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results Circ Cardiovasc Interv 4 2011 495 504
100. M.D. Dake, G.M. Ansel, M.R. Jaff, et al. for the Zilver PTX Investigators Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies [published correction appears in J Am Coll Cardiol 2013;62:666] J Am Coll Cardiol 61 2013 2417 2427
101. G. Tepe, T. Zeller, T. Albrecht, and et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg N Engl J Med 358 2008 689 699
102. M. Werk, S. Langner, B. Reikensmeier, and et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial [published correction appears in Circulation 2008;118:e670] Circulation 118 2008 1358 1365
103. D. Scheinert, S. Duda, T. Zeller, and et al. The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty J Am Coll Cardiol Intv 7 2014 10 19
104. T. Zeller, A. Rastan, R. Macharzina, and et al. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions J Endovasc Ther 21 2014 359 368
105. D. Scheinert, K.L. Schulte, T. Zeller, J. Lammer, and G. Tepe Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BOLUX P-I randomized trial J Endovasc Ther 22 2015 14 21
106. K. Rosenfield, M.R. Jaff, C.J. White, et al. for the LEVANT 2 Investigators Trial of a paclitaxel-coated balloon for femoropopliteal artery disease N Engl J Med 373 2015 145 153
107. J.R. Laird, P.A. Schneider, G. Tepe, et al. for the IN.PACT SFA Investigators Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA J Am Coll Cardiol 66 2015 2329 2338
108. M. Schillinger, S. Sabeti, C. Loewe, and et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery N Engl J Med 354 2006 1879 1888
109. P. Dick, H. Wallner, S. Sabeti, and et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions Catheter Cardiovasc Interv 74 2009 1090 1095
110. H. Krakenberg, M. Schlüter, H.J. Steinkamp, and et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the Femoral Artery Stenting Trial (FAST) Circulation 116 2007 285 292
111. G. Tepe, B. Schnorr, T. Albrecht, and et al. Angioplasty of femoral-popliteal arteries with drug coated balloons: 5-year follow-up of the THUNDER trial J Am Coll Cardiol Intv 8 2015 102 108
112. G. Tepe, J. Laird, P. Schneider, et al. for the IN.PACT SFA Trial Investigators Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial Circulation 131 2015 495 502
113. M. Werk, T. Albrecht, D.R. Meyer, and et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial Circ Cardiovasc Interv 5 2012 831 840
114. O. Iida, H. Yokoi, Y. Soga, et al. for the STOP-IC investigators Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol Study Circulation 127 2013 2307 2315
115. J. Lammer, T. Zeller, K.A. Hausegger, and et al. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease) J Am Coll Cardiol 62 2013 1320 1327
116. J. Lammer, T. Zeller, K.A. Hausegger, and et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial [published correction appears in Cardiovasc Intervent Radiol 2015;38:779-780] Cardiovasc Intervent Radiol 38 2015 25 32
117. P.J. Geraghty, M.W. Mewissen, M.R. Jaff, G.M. Ansel for the VIBRANT Investigators Three-year results of the VIBRANT Trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease J Vasc Surg 58 2013 386 395.e4
118. K. McQuade, D. Gable, G. Pearl, B. Theune, and S. Black Four-year randomized prospective comparison of percutaneous ePTFE/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease J Vasc Surg 52 2010 584 590 discussion 590-1, 591.e1-e7
119. A.W. Bradbury, D.J. Adam, J. Bell, et al. for the BASIL Trial Participants Bypass Versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: analysis of amputation free and overall survival by treatment received [published correction appears in J Vasc Surg 2010;52:1751] J Vasc Surg 51 2010 18S 31S
120. D. Scheinert, K. Katsanos, T. Zeller, et al. for the ACHILLES Investigators A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial J Am Coll Cardiol 60 2012 2290 2295
121. M. Bosiers, D. Scheinert, P. Peeters, and et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease J Vasc Surg 55 2012 390 398
122. A. Rastan, G. Tepe, H. Krakenberg, and et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial Eur Heart J 32 2011 2274 2281
123. F. Liistro, I. Porto, P. Angioli, and et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia Circulation 128 2013 615 621
124. T. Zeller, I. Baumgartner, D. Scheinert, et al. for the IN.PACT DEEP Trial Investigators Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial J Am Coll Cardiol 64 2014 1568 1576
125. D. Siablis, P.M. Kitrou, S. Spiliopoulos, K. Katsanos, and D. Karnabatidis Paclitaxel-coated balloon angioplasty versus dug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial J Am Coll Cardiol Intv 7 2014 1048 1056
126. B.H. Gray, L.J. Diaz-Sandoval, R.S. Dieter, M.R. Jaff, and C.J. White SCAI expert consensus statement for infrapopliteal arterial intervention appropriate use Catheter Cardiovasc Interv 84 2014 539 545
127. A. Rastan, K. Brechtel, H. Krakenberg, and et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial J Am Coll Cardiol 60 2012 587 591
128. A. Farber, K. Rosenfield, and M. Menard The BEST-CLI Trial: a multidisciplinary effort to assess which therapy is best for patients with critical limb ischemia Tech Vasc Interv Radiol 17 2014 221 224